NDA 218709 · X4 Pharms
Xolremdi
Mavorixafor · Oral · CXC Chemokine Receptor 4 Antagonist
NovelPriority reviewOrphanCDER novel approval, Apr 26, 2024: To treat WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)
Last checked: Nov 19, 2026Latest source record: Apr 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Apr 26, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
16
2 Phase 3, 1 recruiting
FAERS reports
8
5 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 12, 2024.
XOLREMDI is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lympocytes. XOLREMDI is a CXC chemokine receptor 4 antagonist indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. ( 1 )
Mechanism: Mavorixafor is an orally bioavailable CXCR4 antagonist that blocks the binding of the CXCR4 ligand, stromal-derived factor-1α (SDF-1α)/CXC Chemokine Ligand 12 (CXCL12). SDF-1/CXCR4 plays a role in trafficking and homing of leukocytes to and from the bone marrow compartment. Gain of function mutations in the CXCR4 receptor gene that occur in patients with WHIM syndrome lead to increased responsiveness to CXCL12 and retention of leukocytes in the bone marrow. Mavorixafor inhibits the response to CXCL12 in both wild‑type and for mutated CXCR4 variants associated with WHIM syndrome. Treatment...
Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 26, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- XOLREMDI · MAVORIXAFOR 100MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Mavorixafor" as an intervention, any sponsor and status, largest first.
- A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsPivotal-lookingRecruiting
X4 PharmaceuticalsIndustry
NCT06056297 · 176 participants (planned) · Start Jun 6, 2024 · Primary completion Sep 2027
Drug: Mavorixafor; Placebo · For: Neutropenia
Sites: Phoenix, Arizona; Irvine, California; La Jolla, California · 115 sites in all
X4 PharmaceuticalsIndustry
NCT02667886 · 74 participants · Start Apr 27, 2016 · Primary completion Apr 14, 2022
Drug: X4P-001; axitinib · For: Clear Cell Renal Cell Carcinoma
Sites: Scottsdale, Arizona; Washington D.C., District of Columbia; Jacksonville, Florida · 20 sites in all
- Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected MenCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00063804 · 44 participants
Drug: Ritonavir; AMD070 · For: HIV Infections
Sites: Baltimore, Maryland; Seattle, Washington
X4 PharmaceuticalsIndustry
NCT07902830 · 40 participants (planned) · Start Dec 2026 · Primary completion Jan 30, 2029
Drug: Mavorixafor · For: Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders; Chronic Neutropenia; Autoimmune Neutropenia and 1 more
X4 PharmaceuticalsIndustry
NCT06858696 · 39 participants · Start Feb 28, 2025 · Primary completion Jan 12, 2026
Drug: Mavorixafor · For: Hepatic Insufficiency
Sites: Montclair, California; Rialto, California; Orlando, Florida · 4 sites in all
X4 PharmaceuticalsIndustry
NCT06914869 · 38 participants · Start Feb 18, 2025 · Primary completion May 19, 2025
Drug: Mavorixafor; Carbamazepine and 1 more · For: Healthy Participants
Sites: Baltimore, Maryland
X4 PharmaceuticalsIndustry
NCT04154488 · 32 participants · Start Oct 16, 2021 · Primary completion Aug 27, 2024
Drug: Mavorixafor · For: Neutropenia
Sites: St. Petersburg, Florida; Iowa City, Iowa; Ann Arbor, Michigan · 7 sites in all
- Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromePivotal-lookingCompleted
X4 PharmaceuticalsIndustry
NCT03995108 · 31 participants · Start Oct 24, 2019 · Primary completion Dec 23, 2025
Drug: Mavorixafor; Placebo · For: WHIM Syndrome
Sites: San Diego, California; Thousand Oaks, California; Iowa City, Iowa · 23 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product administration error3
- nausea2
- product storage error2
- alopecia1
- anaemia1
- antidepressant discontinuation syndrome1
- arthralgia1
- bacteraemia1
- bone pain1
- bronchopulmonary aspergillosis allergic1
- clostridium difficile colitis1
- covid-191
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome.
Badolato R, Alsina L, Azar A, et al. · Blood 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
Choueiri TK, Atkins MB, Rose TL, et al. · Invest New Drugs 2021 · Clinical Trial, Phase I, Multicenter Study
- Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.
Dale DC, Firkin F, Bolyard AA, et al. · Blood 2020 · Clinical Trial, Phase II, Multicenter Study
- Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.
Andtbacka RHI, Wang Y, Pierce RH, et al. · Cancer Res Commun 2022 · Clinical Trial, Phase I
- Dale DC, Firkin F, Bolyard AA, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood. 2020;136(26):2994-3003.
· Blood 2023 · Clinical Trial, Phase II, Published Erratum
- Oral CXCR4 inhibition with mavorixafor: Emerging therapeutic applications in WHIM syndrome, chronic neutropenia, oncology, and stem cell mobilization.
Huynh L, Nguyen CH · Curr Res Transl Med 2026 · Systematic Review
Sponsor: X4 Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.